COVID-19疫苗接种与系统性自身免疫性风湿病:VAERS未显示不成比例报告增加
该研究基于VAERS数据库2020年12月至2024年12月的约68万份有效不良事件报告,采用回顾性不成比例分析,比较COVID-19疫苗与其他疫苗在系统性自身免疫性风湿病(SARDs)报告上的差异。结果显示,未发现任何SARD存在显著不成比例报告信号,其他血管炎类别在COVID-19疫苗接种后报告频率反而较低,性别分层分析结果一致。结论支持COVID-19疫苗在自身免疫风湿事件方面具有良好安全性。
要点
- 基于VAERS约68万份报告的不成比例分析未发现COVID-19疫苗与任何SARD报告增加相关。
- 其他血管炎类别在COVID-19疫苗接种后报告频率低于其他疫苗。
- 性别分层分析结果一致,支持COVID-19疫苗在自身免疫风湿事件方面的良好安全性。
核心结论
- 在大型国家药物警戒数据集中,COVID-19疫苗与任何SARD报告的不成比例增加无关。
研究设计与样本
- 回顾性不成比例分析,使用VAERS数据库2020年12月至2024年12月约68万份有效不良事件报告,比较COVID-19疫苗(BNT162b2、mRNA-1273、Ad26.COV2.S)与所有其他疫苗。
主要发现
- 未发现任何SARD存在显著不成比例报告信号,包括风湿性多肌痛、巨细胞动脉炎、系统性红斑狼疮、系统性硬化症、干燥综合征和肌炎。
- 其他血管炎类别在COVID-19疫苗接种后报告频率低于其他疫苗。
- 性别分层分析结果一致。
关键数值与推荐
- 计算比例报告比(PRR)、报告比值比(ROR)和贝叶斯信息成分(IC),比较COVID-19疫苗与其他疫苗。
临床怎么用
- 结果支持COVID-19疫苗在自身免疫风湿事件方面的良好安全性,同时强调对罕见免疫介导反应进行持续上市后监测的价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate whether systemic autoimmune rheumatic diseases (SARDs) were disproportionately reported as adverse events following COVID-19 vaccination compared with other vaccines, using data from the Vaccine Adverse Event Reporting System (VAERS). METHODS: We conducted a retrospective disproportionality analysis of VAERS reports collected between December 2020 and December 2024. Reports were identified using a structured query based on MedDRA terms for specific SARDs, including polymyalgia rheumatica, giant cell arteritis, systemic lupus erythematosus, systemic sclerosis, Sjögren's syndrome, myositis, and other vasculitides. For each disease, the proportional reporting ratio (PRR), reporting odds ratio (ROR), and Bayesian information component (IC) were calculated, comparing COVID-19 vaccines (BNT162b2, mRNA-1273, Ad26.COV2.S) with all other vaccines in VAERS. Analyses were further stratified by sex to explore consistency. RESULTS: Among approximately 680,000 valid adverse event reports, encompassing both COVID-19 and non-COVID-19 vaccines, no significant disproportionality signal was identified for any SARD. Polymyalgia rheumatica, giant cell arteritis, systemic lupus erythematosus, systemic sclerosis, Sjögren's syndrome, and myositis showed no evidence of disproportionate reporting following COVID-19 vaccination. The category "other vasculitides" displayed a lower reporting frequency following COVID-19 vaccination compared with other vaccines. Stratified analyses yielded consistent findings across sex subgroups. CONCLUSION: In a large national pharmacovigilance dataset, COVID-19 vaccines were not associated with a disproportionate increase in reports of any SARD. These results support the favorable safety profile of COVID-19 vaccines with respect to autoimmune rheumatic events, while highlighting the value of ongoing post-marketing surveillance for rare immune-mediated reactions.
引用
- Ciaffi J, Torrigiani G, Ruscitti P, et al. COVID-19 vaccination and systemic autoimmune rheumatic diseases: No evidence of disproportionately increased reporting in VAERS. Semin Arthritis Rheum. 2026. PMID: 41500053. doi:10.1016/j.semarthrit.2025.152911
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。